Global Animal Biotechnology Market 2025 – 2034

Reports Description

Global Animal Biotechnology Market was valued at USD 28.23 Billion in 2025 and is expected to reachUSD 49.25 Billion by 2034, at a CAGR of 5.77% during the forecast period 2025-2034.

To learn more about this report - request a sample report PDF

Animal Biotechnology Market Overview

The global animal biotechnology market involves the use of molecular biology and genetic engineering technologies to enhance the health, productivity, and reproduction of both food and companion animals. The global animal biotechnology market includes all aspects of genetically modified animals, cloning, transgenics, vaccine development, diagnostics, pharmaceuticals, etc. Animal biotechnology encompasses methods that may improve animal nutrition, disease resistance, and breeding, resulting in improved agricultural productivity and better veterinary health care.

The animal biotechnology market seeks to contribute to real-world problems such as food security, zoonoses, and sustainable animal farming practices. The animal biotechnology sector combines science and expertise from the fields of biotechnology, veterinary medicine, and genomics to determine new and improved animal husbandry practices.

Animal Biotechnology Market Growth Factors

Increasing Demand for Animal-Derived Food Products

An increase in global demand for animal-based food products, especially meats, dairy products, and eggs, continues to fuel momentum in the animal biotechnology market. The world is expected to exceed a total population of 9 billion people by the year 2050, and the issue of food security remains one of the biggest contemporary challenges governments and interested parties of industry face.

This increased demand generates stress for livestock producers to raise productivity and efficiency while offsetting losses due to animal diseases. Animal biotechnology is important to help with these pressures through genetic improvement, precision breeding, and disease-resistant livestock. For example, many farmers in India and China, the largest meat and dairy consumers, have utilized biotech-assisted livestock breeding to increase the milk yield and prevent prevalent diseases like mastitis.

Genetically improved animals are helping ranchers in Brazil increase total beef production and lessen their feed costs. Biotechnology solutions deliver substantive increases in feed conversion ratios and growth performance, and thus profitability and sustainability.

Biotech processes, such as embryo transfer and clone technologies, facilitate the expansion and accelerated propagation of genetically superior and high-yield animals and help alleviate the supply gap in developing regions. The global need for more protein-rich diets, particularly in cities facing growing urbanization, will also broaden the market scope for animal biotechnology.

Technological Advancements in Genetic Engineering and Diagnostics

The animal biotechnology market is being bolstered by rapid advances in genetics and diagnostics. Genetic engineering technologies (i.e., CRISPR-Cas9), gene editing, and transgenic animal models now allow scientists great precision for manipulating animal specificity in animal genomes for increasing desirable traits and minimizing genetic impairments.

By utilizing these technological developments, breeding programs can be accelerated, and they lessen the burden of reliance on traditional breeding procedures, which can be laborious at best and inaccurate at worst. For example, Recombinetics, a US-based company, has gene-edited pigs that are now resistant to Porcine Reproductive and Respiratory Syndrome (PRRS), which is costing the US pork industry more than 600 million dollars annually.

Similarly, AgResearch, a biotechnology company in New Zealand, is using transgenic sheep that produce sheep with superior wool and produce greater quantities of milk, helping to increase New Zealand farm exports. Advancements in diagnostic tools, such as rapid test kits and biosensors, are facilitating the rapid detection of diseases, such as foot-and-mouth disease, avian influenza, and a range of other pathogens.

The rapid detection of pathogens allows for non-targeted, early detection, critical for outbreak management. Portable, hand-held PCR and point-of-care diagnostics are fitting in rural and remote areas. By monitoring the health of animals and quality of meat, they enable quicker and more informed responses to potential threats to animal health and human health, and food quality.

Rising Awareness of Animal Welfare and the One Health Approach

As more people across the globe become interested in animal welfare and the 'One Health' policy highlights the interface between human beings, animals, and the environment, new opportunities are arising in the animal biotechnology industry. The interface between human health professionals, veterinarians, and the environmental profession is a continuous opportunity for innovations in the animal biotechnology industry, as it addresses common health issues.

The tripartite paradigm recognizes that the health of humans, animals, and the environment is inextricably linked, which is encouraging countries around the world, as well as large international organizations and private sector entities, to invest heavily in animal health research, such as zoonotic disease risk mitigation and antimicrobial resistance monitoring.

For example, during the COVID-19 pandemic, numerous zoonotic origin studies recognized the ongoing need for improved disease surveillance in animals, resulting in additional investment in biotechnology-based animal vaccines and diagnostics. Animal welfare laws are also tightening, with countries like Sweden, Germany, and the Netherlands now enforcing humane livestock treatment and breeding without stress.

As a result, there is greater interest in new biotech innovations that enhance health without antibiotics or growth hormones. Zoetis and Merck Animal Health are among the companies developing biotech-based vaccines and new immunomodulators to lessen animal stress and enhance immune response. Increased pet adoption and awareness, alongside personalized veterinary healthcare that uses animal biotechnology methods, such as gene-based diagnostics and regenerative therapies, have further compelled growth in the pet food industry. As societies continue to expand in the adoption of ethical farming and sustainable health ecosystems, animal biotechnology will be front and center in the transformation.

Animal Biotechnology Market Restraints

Complex and Stringent Regulatory Frameworks

One of the major constraints impacting the expansion of the global animal biotechnology market is the highly complex and rigid regulatory framework across regions. Biotechnology-based animal products, especially genetically modified organisms (GMOs), have long and costly approval processes typically associated with safety, environmental, and other ethical considerations.

This regulatory environment also discourages small and mid-size biotech firms from entering the market, which creates a monopoly for larger multinationals. In the European Union, genetically modified animal products are more difficult to regulate than plant GMOs, and this has inhibited a higher degree of innovation in biotechnology-based animal products.

In the United States, genetically modified animals like AquaBounty’s fast-growing salmon took nearly two decades to get commercial approval, even though the regulatory process for approvals by the Food and Drug Administration (FDA) is more structured and follows an approval process. Such extended approval delays increase R&R costs, reduce investor confidence, and subsequently slow commercialization.

And then there are the inconsistent regulations across the board. These inconsistencies are already complicating market expansions and licensing of globally available products, and they're usually not favorable for scalability. For example, Brazil has allowed genetically engineered cattle for enhanced reproduction traits, while its neighbors have either moratoriums (as in Argentina and Paraguay) or agronomic bans (as in Uruguay) on genetically engineered crops.

Doing cross-border trade becomes almost impossible. This situation underscores the need for supply chain participants to call for a unified global standard and regulatory framework based on science. However, all market participants will differentiate compliance and time to market under incompatible jurisdictions, in turn cutting time to market and slowing overall market movement.

Animal Biotechnology Market Trends

Emergence of Precision Livestock Farming (PLF).

The animal biotechnology field is currently undergoing transformational change with the emergence of Precision Livestock Farming (PLF), both in terms of all new data-intensive technologies and advances in genetics and health. The technologies in PLF include wearables, devices, artificial intelligence software, machine learning processes, and other information technologies.

PLF approaches can track how animals behave, their health parameters, when they go into heat, and even environmental conditions, all in real time. PLF technologies maximize the productivity of animals and allow animal producers to implement specific applications of biotech-based solutions. For example, at the Teagasc Research Centre in Ireland, the research team uses wearables that provide health-monitoring information to AI-based software to empower veterinarians to predict disease outbreaks and recommend specific biotech-based vaccinations or supplements.

In Denmark, there are pig farms with sound sensors that tell the farmers when their young pigs have gotten respiratory disease so that they can respond with notifications about genetic remediation or potential isolation strategies. Moreover, gene expression data involving PLF systems also allows biotech companies to relate genetic edits to specific farms. The added integration of biotechnology and digital technologies will allow for faster predictive animal health and animal care services while reducing waste and improving sustainability.

Smart farming is developing in multiple areas, particularly in global developed countries and technology-centered agribusinesses, which makes PLF a crucial platform for innovative animal biotechnology future applications. Furthermore, it offers numerous other possibilities in real-time diagnostics, remote biotech solutions, breeding smarter, and sophisticated technologies that can fast-track a transition towards smarter and ethical animal production systems.

Animal Biotechnology Market Segmentation Analysis.

Based on the product global animal biotechnology market is segmented into diagnostics tests, biologics, drugs, reproductive & genetic. Diagnostic Tests continues to lead the world market for animal biotechnology. This is largely because zoonotic and infectious diseases are becoming more prevalent in livestock and companion animals. The veterinary healthcare ecosystem is utilizing more veterinary diagnostics to facilitate the early diagnosis of infectious disease, mitigate financial losses, and improve outcomes.

Several infectious diseases, such as avian influenza, foot-and-mouth disease in livestock, and brucellosis, have diminished livestock productivity due to consumption and animal health concerns. This has resulted in governments and private stakeholders increasing funding for the development and application of molecular diagnostic processes like PCR, ELISA, and biosensors. In addition, regulatory environments in jurisdictions like the U.S. and the E.U. require diagnostic testing for animal disease regularly for exporters, which has increased demand.

Technological advances in point-of-care testing, such as biosensors, have also made animal diagnostics more accessible, particularly in rural settings. Companies including IDEXX Laboratories and Zoetis are developing their respective portfolios of rapid tests, ultimately supporting early diagnosis and health surveillance efforts. The right tests enable prevention of disease and real-time monitoring that aligns well with a One Health approach, and future growth potential and continued market leadership for this segment in animal biotechnology.

Based on the application global animal biotechnology market is segmented into diagnosis of animal diseases, treatment of animal diseases, preventive care of animals, and other applications. The diagnosis of animal diseases segment dominates the market, which holds the largest share because it forms the basis of veterinary care and disease management strategies.

The increase in incidence of livestock diseases, coupled with an increasing oversight of regulations, has made early and effective diagnosis an important area of consideration in managing animal health. Early diagnosis can help reduce treatment costs, act to stop the disease from spreading, and help protect the supply chain of food derived from animals.

For example, governments in countries such as China, India, and Brazil, major livestock producers provide subsidized diagnostic testing and implement various forms of incentive programs to control endemic diseases such as Newcastle disease or bovine tuberculosis.

Additionally, the increase in the application of biotechnology as part of veterinary medicine has traditionally improved test accuracy, speed, and volume of tests and thus facilitates the increasing reliance on diagnostics. Companion animal healthcare diagnostics, cancer diagnostics, metabolic disease diagnostics, and genetic disease diagnostics are increasing in popularity, all aided by a growing number of pets and a growing willingness to spend on preventive diagnostics.

BIOTECH-enabled platforms are increasingly used by veterinary hospitals and vet diagnostics labs to provide reports to make critical clinical decisions, making diagnostics a key support but now a driver of animal health economics. The application of diagnostics across species has a significantly growing focus in the animal context, categorically suggesting it will be the top-performing application in the industry.

Report Scope

Animal Biotechnology Market Regional Insight

North America has the largest revenue share of the animal biotechnology market, owing to an impressive veterinary infrastructure and high pet ownership paired with substantial investment in animal health technology. The United States is the largest country in the region, largely due to an advanced research and development ecosystem, organization, and active regulatory agencies, including the USDA and FDA, that foster a healthy environment for deploying the latest tools, including animal diagnostics, biologics, and genetic therapies.

With the emergence of zoonotic disease surveillance programs and a growing movement toward precision livestock farming, there is a growing demand for biotech-based animal health solutions. Companies in North America, like Zoetis, Elanco, and IDEXX Laboratories, are rolling out the latest diagnostics or vaccines for both companion animals and farm animals.

The trend of "pet humanization" has also been a major factor in the growth of the region, with pet owners increasingly choosing preventive care services, genetic testing, and targeted therapeutics. There has also been a growth in public-private partnerships in North America (i.e., partnerships between veterinary schools and biotech companies), which have encouraged translational research in animal genomics.

As a result, North America remains the largest market overall due to the high per capita spending on pet care and the increasing proactive planning regarding animal disease management, which provides the resources needed for innovation and commercialization of animal biotechnology.

The Asia-Pacific region is rapidly emerging as the fastest-growing market for animal biotechnology, as there is a large livestock base, a greater awareness of animal health, and an increase in investment in veterinary infrastructure. The livestock sector in countries such as China, India, Australia, and South Korea is driving demand for testing, vaccines, and breeding solutions from biotechnology as part of a growing demand for food security and productivity.

Governments are rushing to employ biotechnology in controlling epidemics of diseases such as foot-and-mouth disease, swine fever, and bird flu. In India, for instance, the National Animal Disease Control Programme (NADCP) seeks to vaccinate more than 500 million animals against FMD and brucellosis, creating opportunities in vaccine and diagnostic firms.

China is also increasing investment in animal genomics research as part of its overall rural modernization plans, increasing the number of genetic selection tools available and enhancing livestock outputs. Multinational companies are also extending their footprint in Asia-Pacific by partnering with local players and launching products.

The rising incomes of the middle class, especially in urban areas, have accompanied increasing pet ownership and personalized services from veterinarians, further establishing Asia-Pacific as a growth engine for the global animal biotechnology marketplace through increased government initiatives, awareness, and commercial interest.

Animal Biotechnology Market Recent Developments

• In September 2024, Bioassay GmbH obtained a GMP Manufacturing License for its veterinary products manufacturing plant in Germany for bioanalytical testing solutions.

• In September 2024, animal health products leader Zoetis enlarged its existing veterinary medicine and vaccine manufacturing plant in Hyderabad, India, to produce sophisticated veterinary technological tools in an efficient manner.

• In August 2024, Fischer Medical Ventures (India) collaborated with Bio Angle Vacs Sdn Bhd (Malaysia) for the commercialization & development of new-age vaccines to tackle mortality rates of aquaculture and livestock in India.

List of the prominent players in the Animal Biotechnology Market:

• Zoetis
• Boehringer Ingelheim
• Merck & Co. Inc.
• Virbac
• Elanco
• Idexx Laboratories
• Dechra Pharmaceuticals
• Heska Corporation
• Indian Immunologicals Ltd
• Hester Biosciences Pvt. Ltd
• Biogénesis Bagó
• Others

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America